 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Jazz Pharmaceuticals (JAZZ) is a specialty biopharmaceutical company. The company focuses on the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs.
Its marketed products include Xyrem, a sodium oxybate oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; FazaClo (clozapine, USP) LD and FazaClo HD products, which are orally disintegrating clozapine tablets for the treatment of resistant schizophrenia; Luvox CR extended-release capsules for the treatment of obsessive compulsive disorder; and Prialt, a non-opioid intrathecal analgesic for refractory severe chronic pain.
The company also offers womens health and other products, such as Elestrin for moderate-to-severe vasomotor symptoms associated with menopause; Natelle and Gesticare prescription prenatal vitamins; Urelle for irritative voiding, as well as for inflammation, hypermotility, and pain that accompany lower urinary tract infections; Gastrocrom oral concentrate for mastocytosis; Parcopa for idiopathic Parkinsons disease; and AVC (sulfanilamide) cream to treat vulvovaginitis caused by Candida albicans, as well as Niravam for the management of anxiety disorder or the short-term relief of symptoms of anxiety, as well as for panic disorder with or without agoraphobia.
Shares have formed a bullish "flag" and trading volume has dwindled. That should be a good entry point for the stock. In flag formations, when trading volume is reduced, it is an indication that stock is running out of sellers. Higher prices are expected from here.
52-Week Trading Range: $34.02 - $60.00
Last Trade: $56.20
Stop Loss: $53.39
Target Price: $61.80
